1. Using diagnosis-related groups

   • M. Lungen
   • B. Dredge
   • and the Working Group

   Editorial Pages: 287 - 289

2. Re-scaling social preference data: implications for modelling

   • Irina Cleemput
   • Paul Kind
   • Katrien Kesteloot

   Original Papers Pages: 290 - 298

   

3. Willingness to pay for dental fear treatment

   • Bente Halvorsen
   • Tiril Willumsen

   Original Paper Pages: 299 - 308

   

4. What reimbursement for coronary revascularization with drug-eluting stents?

   • Rosanna Tarricone
   • Monia Marchetti
   • Peter de Jong

   Original paper Pages: 309 - 316

   

5. A method for cross-sector priority setting

   • Tugrul Temel

   Original papers Pages: 317 - 323

   

6. Drug price regulation under consumer moral hazard

   • Stefan Felder

   Original Paper Pages: 324 - 329

   

7. Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy

   • Iva Krulichova
   • Sara Gamba
   • on behalf of the Italian Takayasu Arteritis Study Group

   Original paper Pages: 330 - 334

8. A note on the impact of hours worked on mortality in OECD countries

   • Edvard Johansson

   Original paper Pages: 335 - 340

9. The high cost of medicines in Ireland

   • Lesley Tilson
   • Bernadette McGowan
   • Michael Barry

   Original paper Pages: 341 - 344

10. Approval times and the safety of new pharmaceuticals

    • Niklas Rudholm

    Original paper Pages: 345 - 350

11. Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden

    • Joakim Ramsberg
    • Stefan Odeberg
    • Douglas Lundin

    Pricing and reimbursement Pages: 351 - 356

    

12. Data envelopment analysis based bonus payments

    • Stefan Felder
    • Horst Schmitt

    Congress Papers Pages: 357 - 364

    

13. Exponential health utility

    • Lars Peter Østerdal

    Original papers Pages: 365 - 367